ANNX
Closed
Annexon inc
2.47
+0.07 (+2.92%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.4
Day's Range: 2.3 - 2.53
Send
sign up or login to leave a comment!
When Written:
3.85
Annexon Inc is a biopharmaceutical company that develops therapies for patients with classical complement-mediated disorders. The company's lead product candidate, ANX005, is a monoclonal antibody that targets C1q, a protein in the complement system that plays a key role in autoimmune and neurodegenerative diseases. Annexon was founded in 2011 and is headquartered in South San Francisco, California. The company has raised over $300 million in funding from investors such as New Enterprise Associates, Novartis Venture Fund, and Blackstone Life Sciences. Annexon has also entered into partnerships with pharmaceutical companies such as Takeda and Celgene.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








